Trilaciclib
Cosela (trilaciclib) is a small molecule pharmaceutical. Trilaciclib was first approved as Cosela on 2021-02-12. It is known to target cyclin-dependent kinase 4, cyclin-dependent kinase 6, cyclin-dependent kinase 7, cyclin-dependent kinase 9, and cyclin-dependent kinase 2.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Cosela
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Trilaciclib dihydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| COSELA | Pharmacosmos | N-214200 RX | 2021-02-12 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| cosela | New Drug Application | 2023-08-03 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
TRILACICLIB DIHYDROCHLORIDE, COSELA, G1 THERAP | |||
| 2026-02-12 | NCE | ||
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Trilaciclib Dihydrochloride, Cosela, G1 Therap | |||
| 11529352 | 2039-07-23 | U-3504 | |
| 9487530 | 2034-03-14 | U-3079, U-3080 | |
| 10085992 | 2034-03-14 | U-3081 | |
| 10966984 | 2034-03-14 | U-3079, U-3080 | |
| 11040042 | 2034-03-14 | DP | |
| 11717523 | 2034-03-14 | U-3678, U-3679 | |
| 8598186 | 2031-10-25 | DS, DP | |
| 8598197 | 2031-10-25 | DS, DP | |
| 9957276 | 2031-10-25 | DP | |
| 10189849 | 2031-10-25 | DP | |
| 10189850 | 2031-10-25 | DP | |
| 10927120 | 2031-10-25 | DP | |
HCPCS
Code | Description |
|---|---|
| J1448 | Injection, trilaciclib, 1mg |
Clinical
Clinical Trials
35 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lung neoplasms | D008175 | HP_0100526 | C34.90 | 2 | 8 | 1 | 2 | 1 | 12 |
| Small cell lung carcinoma | D055752 | — | — | 2 | 5 | 1 | 2 | 1 | 9 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 8 | 1 | — | — | 9 |
| Triple negative breast neoplasms | D064726 | — | — | — | 5 | 1 | — | — | 6 |
| Urinary bladder neoplasms | D001749 | — | C67 | — | 1 | 1 | — | — | 2 |
| Transitional cell carcinoma | D002295 | — | — | — | 1 | 1 | — | — | 2 |
| Colorectal neoplasms | D015179 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-small-cell lung carcinoma | D002289 | — | — | — | 7 | — | — | — | 7 |
| Hemangiosarcoma | D006394 | — | — | — | 1 | — | — | — | 1 |
| Neoplasms | D009369 | — | C80 | — | 1 | — | — | — | 1 |
| Neutropenia | D009503 | — | D70 | — | 1 | — | — | — | 1 |
| Urologic neoplasms | D014571 | — | C64-C68 | — | 1 | — | — | — | 1 |
| Carcinoma | D002277 | — | C80.0 | — | 1 | — | — | — | 1 |
| Chemotherapy-induced febrile neutropenia | D064146 | — | — | — | 1 | — | — | — | 1 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | — | 1 | — | — | — | 1 |
| Osteosarcoma | D012516 | — | — | — | 1 | — | — | — | 1 |
| Endometrial neoplasms | D016889 | EFO_0004230 | — | — | 1 | — | — | — | 1 |
Show 7 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Squamous cell carcinoma | D002294 | — | — | — | — | — | — | 1 | 1 |
| Esophageal squamous cell carcinoma | D000077277 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Trilaciclib |
| INN | trilaciclib |
| Description | Trilaciclib, sold under the brand name Cosela, is a medication used to reduce the frequency of chemotherapy-induced bone marrow suppression.
|
| Classification | Small molecule |
| Drug class | cyclin dependent kinase inhibitors (formerly-cidib) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CN1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CC1 |
Identifiers
| PDB | — |
| CAS-ID | 1374743-00-6 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3894860 |
| ChEBI ID | — |
| PubChem CID | 68029831 |
| DrugBank | DB15442 |
| UNII ID | U6072DO9XG (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 336 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
185 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use